Revenue
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals, Inc. (TARS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M | $0 | — | — |
| Research & development | $64.3M | $53.4M | $50.3M | $42.6M | $41.7M | $18.8M | $3.2M | — |
| Operating expenses | — | — | $160.6M | $88.5M | $69.2M | $27.0M | $4.3M | — |
| Operating income | −$71.0M | −$120.6M | −$143.2M | −$62.7M | −$12.2M | −$27.0M | −$4.3M | — |
| EBITDAderived | −$69.2M | −$119.3M | −$142.3M | −$62.4M | — | — | — | — |
| Net income | −$66.4M | −$115.6M | −$135.9M | −$62.1M | −$13.8M | −$26.8M | −$4.7M | −$1.3M |
| Basic EPSper diluted share | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 | -$4.32 | -$1.98 | — |
| Diluted EPSper diluted share | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 | -$4.32 | -$1.98 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Azamian Bobak R.President/CEO and Board Chair | SellCommon Stock · indirect | 5.4K | $61.81 | $334.9K | 848.0K |
| Jun 17, 2026Form 4 · 10b5-1 | Azamian Bobak R.President/CEO and Board Chair | SellCommon Stock · indirect | 4.6K | $61.24 | $280.6K | 853.4K |
| Jun 16, 2026Form 4 | Farrow Jeffrey SSee Remarks | SellCommon Stock | 14.4K | $60.95 | $877.4K | 56.8K |
| Jun 15, 2026Form 4 · 10b5-1 | Goodrich KatherineDirector | SellCommon Stock | 3.0K | $62.08 | $183.4K | 2.2K |
| Jun 15, 2026Form 4 · 10b5-1 | LINK WILLIAM J PHDDirector | SellCommon Stock | 1.9K | $62.94 | $121.3K | 106.8K |